Overview

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether OC (oxybutynin and clonidine) oral solution is effective in reducing saliva secretion in patients suffering from Parkinson's Disease with excessive salivation.
Phase:
Phase 2
Details
Lead Sponsor:
Orient Pharma Co., Ltd.
Treatments:
Clonidine
Oxybutynin
Pharmaceutical Solutions